

# Pneumococcal Vaccines

Nancy M. Bennett, MD, MS  
Pneumococcal Vaccines Work Group Chair  
**Advisory Committee on Immunization Practices**  
June 25, 2015



# Pneumococcal Vaccines Work Group

## ACIP members

Nancy Bennett (Chair)

Arthur Reingold

Allison Kempe

Lorry Rubin

## Ex Officio members

Lucia Lee (FDA)

Tina Mongeau (FDA)

**CDC Lead (CDC/NCIRD)**

Tamara Pilishvili

## Liaison representatives and consultants

Jeff Duchin

Rick Zimmerman (AAFP)

William Schaffner (NFID)

Caroline Quach (NACI)

Mark Sawyer (AAP, PIDS)

Jane Zucker (AIM)

Monica Farley (VA)

Carol Baker (IDSA)

Kathy Neuzil (IDSA)

Keith Klugman

Sandra Fryhofer (ACP, AMA)

# **Pneumococcal Vaccines Work Group: Terms of Reference**

- Review current data on efficacy, effectiveness, immunogenicity, and cost-effectiveness of pneumococcal vaccines
- Review current recommendations considering up-to-date evidence, including epidemiological studies conducted post-licensure, and assess strength of the evidence
- Revise or update recommendations for pneumococcal vaccine use, as needed

# Focus of today's session

- Harmonization of recommended intervals between 13-valent pneumococcal conjugate vaccine (PCV13) and 23-valent pneumococcal polysaccharide vaccine (PPSV23) across age and risk groups
- Proposal for a vote

# Recommendations for PCV13 and PPSV23 use in series

- ❑ Both PCV13 and PPSV23 are recommended for:
  - Adults 65 years or older (ACIP, Aug 2014)
  - Individuals 2-64 years of age (ACIP, Feb 2010, Jun 2012, Jun 2013)
    - Immunocompromising conditions
    - Functional or anatomic asplenia
    - CSF leaks or cochlear implants
- ❑ Recommended sequence: PCV13 → PPSV23
- ❑ PCV13 recommended even if previously received PPSV23
- ❑ Recommended intervals vary by age and risk group, and the vaccine sequence

# Recommended Intervals Between the Two Pneumococcal Vaccines

Age groups	Underlying conditions	PCV13→ PPSV23	PPSV23→ PCV13
24-71mo	<ul style="list-style-type: none"> <li>• Immunocompetent with underlying chronic conditions</li> <li>• Functional or anatomic asplenia</li> <li>• Immunocompromised</li> </ul>	≥8 weeks	≥8 weeks
6-18 years	<ul style="list-style-type: none"> <li>• High-risk immunocompetent (CSF leak, cochlear implants)</li> <li>• Functional or anatomic asplenia</li> <li>• Immunocompromised</li> </ul>	≥8 weeks	≥8 weeks
≥19 years	<ul style="list-style-type: none"> <li>• High-risk immunocompetent (CSF leak, cochlear implants)</li> <li>• Functional or anatomic asplenia</li> <li>• Immunocompromised</li> </ul>	≥8 weeks	≥1 year
≥65 years	NA	6-12 months (minimum 8 weeks)	≥1 year

# Today's session

- ❑ Rational and evidence for the proposed changes to recommended intervals between PCV13 and PPSV23
  - Miwako Kobayashi
- ❑ Proposed changes to recommendations for intervals between PCV13 and PPSV23
  - Tamara Pilishvili
- ❑ ACIP vote